# Glucose Reduction by Early Acarbose Treatment in Basal Insulin

> **NCT00970528** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 124 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Acarbose (Glucobay, BAYG5421)
- **DRUG:** Voglibose (Basen)

## Key facts

- **NCT ID:** NCT00970528
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2014-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970528, "Glucose Reduction by Early Acarbose Treatment in Basal Insulin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00970528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*